EXELMEDIUM SIGNALFINANCIAL10-K

EXEL demonstrates strong profitability growth with substantially higher net income while significantly reducing capital expenditures and increasing share buybacks.

The company appears to be entering a mature phase, generating robust cash flows from operations while pulling back on capital investments. The shift toward increased shareholder returns through expanded buybacks suggests management confidence in the business but potentially limited high-return reinvestment opportunities.

Comparing 2026-02-10 vs 2025-02-11View on EDGAR →
FINANCIAL ANALYSIS

EXEL delivered strong financial performance with substantially higher net income and meaningfully expanded operating income, supported by robust operating cash flow growth of 26%. The company dramatically reduced capital expenditures by 70% while increasing share buybacks by 45%, indicating a strategic shift toward returning cash to shareholders rather than investing in growth infrastructure. This pattern suggests a maturing business model focused on optimizing returns from existing operations.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-70.4%
$28.4M→$8.4M

Capex reduced 70.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Net Income
P&L
+50.1%
$521.3M→$782.6M

Net income grew 50.1% — bottom-line growth signals improving overall business health.

Share Buybacks
Cash Flow
+45.3%
$652.0M→$947.5M

Share repurchases increased 45.3% — management returning capital, signals confidence in intrinsic value.

Operating Income
P&L
+44.3%
$604.6M→$872.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
+26.3%
$700.0M→$884.3M

Operating cash flow grew 26.3% — strong conversion of earnings to cash, healthy business fundamentals.

LANGUAGE CHANGES
NEW — 2026-02-10
PRIOR — 2025-02-11
ADDED
Excludes shares of the registrant s common stock held by persons who were directors and/or executive officers of the registrant at July 4, 2025 on the basis that such persons may be deemed to have been affiliates of the registrant at such date.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 118 Item 9A.
Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications and, to a lesser degree, the continued clinical development, regulatory approval, clinical acceptance and commercial success of the cabozantinib franchise.
Current healthcare laws, policies, and regulations in the U.S.
healthcare system, including those related to drug pricing, may affect our ability to commercialize our marketed products profitably.
+7 more — sign up free →
REMOVED
Excludes shares of the registrant s common stock held by persons who were directors and/or executive officers of the registrant at June 28, 2024 on the basis that such persons may be deemed to have been affiliates of the registrant at such date.
Changes in and Disagreements Wi th Accountants on Accounting and Financial Disclosure 119 Item 9A.
Form 10-K Summary 128 SIGNATURES 129 1 Table of C o n t e n t s SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS Some of the statements under the captions Risk Factors, Management s Discussion and Analysis of Financial Condition and Results of Operations and Business and elsewhere in this Annual Report on Form 10-K are forward-looking statements.
Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications and the continued clinical development, regulatory approval, clinical acceptance and commercial success of the cabozantinib franchise in additional indications.
and in foreign countries, has come under increasing attention and scrutiny by federal, state and foreign national governments, legislative bodies and enforcement agencies.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →